Lipigon Pharmaceuticals AB (LPGO) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.806x

Based on the latest financial reports, Lipigon Pharmaceuticals AB (LPGO) has a cash flow conversion efficiency ratio of -0.806x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.38 Million ≈ $-686.81K USD) by net assets (Skr7.91 Million ≈ $851.67K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Lipigon Pharmaceuticals AB (LPGO) balance sheet quality index to measure how much of total assets are equity-financed.

Lipigon Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Lipigon Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Lipigon Pharmaceuticals AB cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

Lipigon Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lipigon Pharmaceuticals AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Rockfire Resources plc LSE:ROCK	-0.092x
ADVANCED INF SERV(ADVANC) STU:NVAA	0.311x
OCA Acquisition Corp NASDAQ:OCAXU	-0.003x
Safestay PLC LSE:SSTY	0.085x
Livento Group Inc. NASDAQ:NUGND	0.001x
AYURCANN HOLDINGS CORP. F:3ZQ0	0.263x
Fiske PLC LSE:FKE	0.090x
Greenroc Mining PLC LSE:GROC	-0.035x

Annual Cash Flow Conversion Efficiency for Lipigon Pharmaceuticals AB (2018–2025)

The table below shows the annual cash flow conversion efficiency of Lipigon Pharmaceuticals AB from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Lipigon Pharmaceuticals AB (LPGO) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr7.91 Million ≈ $851.67K	Skr-35.77 Million ≈ $-3.85 Million	-4.520x	-41.57%
2024-12-31	Skr7.76 Million ≈ $835.21K	Skr-24.78 Million ≈ $-2.67 Million	-3.193x	-534.28%
2023-12-31	Skr28.44 Million ≈ $3.06 Million	Skr-14.32 Million ≈ $-1.54 Million	-0.503x	+94.80%
2022-12-31	Skr3.87 Million ≈ $416.58K	Skr-37.47 Million ≈ $-4.03 Million	-9.679x	-529.59%
2021-12-31	Skr22.96 Million ≈ $2.47 Million	Skr-35.30 Million ≈ $-3.80 Million	-1.537x	-131.41%
2020-12-31	Skr12.98 Million ≈ $1.40 Million	Skr-8.62 Million ≈ $-928.19K	-0.664x	+74.08%
2019-12-31	Skr2.17 Million ≈ $233.42K	Skr-5.56 Million ≈ $-598.24K	-2.563x	-166.14%
2018-12-31	Skr-842.00K ≈ $-90.61K	Skr-3.26 Million ≈ $-351.15K	3.875x	--

About Lipigon Pharmaceuticals AB

ST:LPGO Sweden Biotechnology

Market Cap

$97.81K

Skr908.90K SEK

Market Cap Rank

#31368 Global

#747 in Sweden

Share Price

Skr0.00

Change (1 day)

-44.44%

52-Week Range

Skr0.00 - Skr0.19

All Time High

Skr10.15